KPTI (Karyopharm Therapeutics) Inventories, Raw Materials & Components: $0.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KPTI Karyopharm Therapeutics Inc KPTI
49 GF Score
Price $2.01
GF Value $4.99
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Inventories, Raw Materials & Components?

Karyopharm Therapeutics KPTI +1.51% 49 Inventories, Raw Materials & Components is $0.6 Mil as of Jun. 2026. GuruFocus rates KPTI with a GF Score™ of 49/100 and a GF Value™ of $4.99 (Possible Value Trap). The stock has 6 warning signs investors should review.

Karyopharm Therapeutics's inventories, raw materials & components for the quarter that ended in Jun. 2026 was $0.6 Mil.

Karyopharm Therapeutics's quarterly raw materials stayed the same from Dec. 2025 ($0.6 Mil) to Mar. 2026 ($0.6 Mil) and stayed the same from Mar. 2026 ($0.6 Mil) to Jun. 2026 ($0.6 Mil).

Karyopharm Therapeutics's annual raw materials increased from Dec. 2023 ($0.6 Mil) to Dec. 2024 ($0.7 Mil) but then declined from Dec. 2024 ($0.7 Mil) to Dec. 2025 ($0.6 Mil).

Karyopharm Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Inventories, Raw Materials & Components Chart

Karyopharm Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.80 1.37 0.55 0.72 0.63

Karyopharm Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.63 0.63 0.63 0.63
KPTI
49GF Score
Karyopharm Therapeutics Inc KPTI
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Karyopharm Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.6 Mil mean?
Karyopharm Therapeutics (KPTI) has a Inventories, Raw Materials & Components of $0.6 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Inventories, Raw Materials & Components too high?
Karyopharm Therapeutics' current Inventories, Raw Materials & Components is $0.6 Mil. Overall, Karyopharm Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Inventories, Raw Materials & Components compare to TNYA and HUMA?
Karyopharm Therapeutics' Inventories, Raw Materials & Components of $0.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Inventories, Raw Materials & Components is $0.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Possible Value Trap. The stock's GF Value™ is $4.99, compared to a current price of $2.01 — trading 59.7% below its estimated fair value. The current Inventories, Raw Materials & Components is $0.6 Mil. Karyopharm Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Inventories, Raw Materials & Components is $0.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be undervalued. The current stock price of $2.01 is trading 59.7% below its estimated GF Value™ of $4.99. GuruFocus considers Karyopharm Therapeutics to be Possible Value Trap.

Key valuation signals for KPTI:

  • Inventories, Raw Materials & Components: $0.6 Mil
  • GF Value™: $4.99 vs. price of $2.01 (59.7% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
49GF Score

Get the complete analysis for KPTI

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.01
Price
$4.99
GF Value